Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canagliflozin - Johnson & Johnson/ Mitsubishi Tanabe Pharma Corporation

Drug Profile

Canagliflozin - Johnson & Johnson/ Mitsubishi Tanabe Pharma Corporation

Alternative Names: Canagliflozin-hydrate; Canaglu; Invokana; JNJ-28431754; Sulisent; TA-7284

Latest Information Update: 17 Jun 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Daiichi Sankyo Company; Janssen; Johnson & Johnson; Mitsubishi Tanabe Pharma Corporation; Miyazaki University School of Medicine
  • Class Antihyperglycaemics; Cardiovascular therapies; Glucosides; Heart failure therapies; Obesity therapies; Small molecules; Thiophenes
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Preregistration Diabetic nephropathies
  • Phase II Heart failure; Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 11 Jun 2019 Efficacy and adverse events data from a subgroup analysis of the phase III CREDENCE trial in Type 2 diabetes mellitus and Diabetic nephropathies released by Janssen Pharmaceuticals
  • 28 May 2019 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(Adjunctive treatment, In adolescents, In children) in Brazil (PO, Capsule)
  • 28 May 2019 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(Adjunctive treatment, In adolescents, In children) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top